Aflibercept for the treatment of neovascular age-related macular degeneration

E. A. Verner-Cole, S. J. Davis, Andreas (Andy) Lauer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Age-related macular degeneration (AMD) can have devastating effects on vision, especially in its neovascular form. In the last decade, the use of intravitreal pharmacotherapy targeted to vascular endothelial growth factor (VEGF) has significantly improved the visual outcomes in patients with neovascular AMD. Although we have become accustomed to these unprecedented improvement outcomes, maintaining good visual results with anti-VEGF therapy requires tremendous effort, time and cost, typically involving monthly clinic visits and intravitreal injections. The introduction of aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown promise throughout recent clinical trials as an equally effective treatment for neovascular AMD that requires less frequent dosing than either ranibizumab or bevacizumab. Based on clinical trial results, the U.S. Food and Drug Administration approved aflibercept in November 2011 for use in neovascular AMD, giving patients the hope of alleviating some of the burden associated with treatment.

Original languageEnglish (US)
Pages (from-to)317-329
Number of pages13
JournalDrugs of Today
Volume48
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Macular Degeneration
Vascular Endothelial Growth Factor A
Clinical Trials
Intravitreal Injections
United States Food and Drug Administration
Therapeutics
Ambulatory Care
Protein Isoforms
Costs and Cost Analysis
Drug Therapy
aflibercept
Pharmaceutical Preparations

Keywords

  • Aflibercept
  • Age-related macular degeneration
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Aflibercept for the treatment of neovascular age-related macular degeneration. / Verner-Cole, E. A.; Davis, S. J.; Lauer, Andreas (Andy).

In: Drugs of Today, Vol. 48, No. 5, 05.2012, p. 317-329.

Research output: Contribution to journalArticle

Verner-Cole, E. A. ; Davis, S. J. ; Lauer, Andreas (Andy). / Aflibercept for the treatment of neovascular age-related macular degeneration. In: Drugs of Today. 2012 ; Vol. 48, No. 5. pp. 317-329.
@article{400f807826cc4ec7a1de6ed95f65775d,
title = "Aflibercept for the treatment of neovascular age-related macular degeneration",
abstract = "Age-related macular degeneration (AMD) can have devastating effects on vision, especially in its neovascular form. In the last decade, the use of intravitreal pharmacotherapy targeted to vascular endothelial growth factor (VEGF) has significantly improved the visual outcomes in patients with neovascular AMD. Although we have become accustomed to these unprecedented improvement outcomes, maintaining good visual results with anti-VEGF therapy requires tremendous effort, time and cost, typically involving monthly clinic visits and intravitreal injections. The introduction of aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown promise throughout recent clinical trials as an equally effective treatment for neovascular AMD that requires less frequent dosing than either ranibizumab or bevacizumab. Based on clinical trial results, the U.S. Food and Drug Administration approved aflibercept in November 2011 for use in neovascular AMD, giving patients the hope of alleviating some of the burden associated with treatment.",
keywords = "Aflibercept, Age-related macular degeneration, Vascular endothelial growth factor",
author = "Verner-Cole, {E. A.} and Davis, {S. J.} and Lauer, {Andreas (Andy)}",
year = "2012",
month = "5",
doi = "10.1358/dot.2012.48.5.1805931",
language = "English (US)",
volume = "48",
pages = "317--329",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "5",

}

TY - JOUR

T1 - Aflibercept for the treatment of neovascular age-related macular degeneration

AU - Verner-Cole, E. A.

AU - Davis, S. J.

AU - Lauer, Andreas (Andy)

PY - 2012/5

Y1 - 2012/5

N2 - Age-related macular degeneration (AMD) can have devastating effects on vision, especially in its neovascular form. In the last decade, the use of intravitreal pharmacotherapy targeted to vascular endothelial growth factor (VEGF) has significantly improved the visual outcomes in patients with neovascular AMD. Although we have become accustomed to these unprecedented improvement outcomes, maintaining good visual results with anti-VEGF therapy requires tremendous effort, time and cost, typically involving monthly clinic visits and intravitreal injections. The introduction of aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown promise throughout recent clinical trials as an equally effective treatment for neovascular AMD that requires less frequent dosing than either ranibizumab or bevacizumab. Based on clinical trial results, the U.S. Food and Drug Administration approved aflibercept in November 2011 for use in neovascular AMD, giving patients the hope of alleviating some of the burden associated with treatment.

AB - Age-related macular degeneration (AMD) can have devastating effects on vision, especially in its neovascular form. In the last decade, the use of intravitreal pharmacotherapy targeted to vascular endothelial growth factor (VEGF) has significantly improved the visual outcomes in patients with neovascular AMD. Although we have become accustomed to these unprecedented improvement outcomes, maintaining good visual results with anti-VEGF therapy requires tremendous effort, time and cost, typically involving monthly clinic visits and intravitreal injections. The introduction of aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown promise throughout recent clinical trials as an equally effective treatment for neovascular AMD that requires less frequent dosing than either ranibizumab or bevacizumab. Based on clinical trial results, the U.S. Food and Drug Administration approved aflibercept in November 2011 for use in neovascular AMD, giving patients the hope of alleviating some of the burden associated with treatment.

KW - Aflibercept

KW - Age-related macular degeneration

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84861980737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861980737&partnerID=8YFLogxK

U2 - 10.1358/dot.2012.48.5.1805931

DO - 10.1358/dot.2012.48.5.1805931

M3 - Article

C2 - 22645720

AN - SCOPUS:84861980737

VL - 48

SP - 317

EP - 329

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 5

ER -